Open Access

Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population

  • Fumihiko Toyoshima1,
  • Tadayuki Oshima1,
  • Shigemi Nakajima2,
  • Jun Sakurai1,
  • Junji Tanaka1,
  • Toshihiko Tomita1,
  • Kazutoshi Hori1,
  • Takayuki Matsumoto3 and
  • Hiroto Miwa1Email author
BMC Medical GeneticsBMC series ¿ open, inclusive and trusted201112:88

DOI: 10.1186/1471-2350-12-88

Received: 25 October 2010

Accepted: 29 June 2011

Published: 29 June 2011

Abstract

Background

Although familial clustering of functional dyspepsia (FD) has been reported, the role of genetics in the susceptibility to FD is still not well understood. In the present study, the association between serotonin transporter (SERT) gene (SLC6A4) polymorphism and FD was explored.

Methods

Subjects were divided into either a postprandial distress syndrome (PDS) group or an epigastric pain syndrome (EPS) group according to the Rome III criteria. The healthy controls were those who had visited a hospital for an annual health check-up. The presence of the SLC6A4 promoter polymorphism, 5-hydroxytryptamin transporter gene linked polymorphic region (5-HTTLPR), was then evaluated, and logistic regression analysis was used to test all variables.

Results

The 5-HTTLPR genotype distribution was 448 SS, 174 SL, and 24 LL in controls and 30 SS, 20 SL, and 3 LL in FD subjects. No significant correlation was found between the 5-HTTLPR genotype and FD. When the genotypes and subtypes of FD were exploratory evaluated, the SL genotype was significantly associated with PDS [odds ratio (OR) = 2.24, 95% confidence interval (CI); 1.16-4.32, P = 0.034 after Bonferroni correction] compared to the SS genotype adjusted for sex and age. Comparison of the SS genotype with the SL/LL genotype also showed a significant association of genotype with PDS (OR = 2.32, 95% CI; 1.23-4.37, P = 0.009).

Conclusion

The present results suggest that 5-HTTLPR L allele may influence the susceptibility to PDS.

Background

Functional dyspepsia (FD) is characterized by the presence of symptoms thought to originate in the gastroduodenal tract in the absence of any organic or systemic disease that explains the symptoms [1]. The precise pathophysiology of the functional gastrointestinal disorders is still unknown. However, several pathophysiological mechanisms have been described as possible etiological factors: visceral hypersensitivity [2, 3], impaired proximal gastric accommodation [4], delayed or early gastric emptying [5], dysfunction of the autonomic nervous system [6], and underlying psychiatric disturbances [7]. Although risk factors for FD, including age, sex, Helicobacter pylori infection, smoking, and psychological disturbances, have also been reported, the data are inconclusive [8, 9].

There is increasing evidence that susceptibility to functional gastrointestinal disorders is influenced by hereditary factors. We have reported the association between G-protein β3 subunit 825TT genotype and EPS-like dyspepsia [10]. IL-17F 7488T/C, migration inhibitory factor G173C [11], catechol-o-methyltransferase gene val158met [12], 779 TC of CCK-1 intron 1 [13], cyclooxygenase-1 T1676C [14], p22 phagocyte oxidase C242T [15], transient receptor potential cation channel, subfamily V, member 1 G315C [16], and regulated upon activation normal T cell expressed and secreted C-28G polymorphisms have also been reported to be associated with the development of FD or dyspeptic symptoms in the Japanese population [17].

Serotonin (5-hydroxytryptamin, 5-HT) is an important signaling molecule affecting gastrointestinal motor and sensory functions. Ninety-five percent of the body's 5-HT is synthesized in enterochromaffin cells in the gut. 5-HT binds to 7 subclasses of serotonergic receptors differentiated on the basis of structure, molecular mechanisms, and function [18]. To terminate serotonergic action, re-uptake occurs by the serotonin transporter protein (SERT) from the synaptic cleft. This protein is encoded by a single gene (SLC6A4) on chromosome 17q11 and is composed of 14 exons [19]. There is a 44-bp insertion/deletion in the 5'-flanking promoter region (5-HT transporter gene linked polymorphic region, 5-HTTLPR), which creates a short and a long allele (S and L allele). The S allele of 5-HTTLPR has been associated with lower transcriptional efficiency than the L allele [20].

Several studies have investigated the association between this functional polymorphism and various complex behavioral traits and disorders, including anxiety [20], major depression [21], suicide [22], smoking behavior [23], alcohol dependence [24], and irritable bowel syndrome [2532]. Only two studies have explored the association between 5-HTTLPR polymorphism and FD. However, there were no significant associations between them [33, 34]. We thought it necessary to undertake a large-scale general population study. In this study, the relationship between the 5-HTTLPR polymorphism and FD was investigated in Japanese patients, with subjects who underwent annual health check-up acting as controls.

Methods

Subjects

A total of 77 subjects with uninvestigated dyspepsia at Hyogo College of Medicine from June 2006 to June 2010 were enrolled. All subjects were Japanese and completed an original self-administered questionnaire that assessed symptoms of dyspepsia, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) according to the ROME III criteria. Dyspeptic symptoms were defined as pain or discomfort in the upper abdomen for the last 3 months, with symptom onset at least 6 months prior to the check-up. Postprandial distress syndrome (PDS) was defined as postprandial fullness and early satiation, and epigastric pain syndrome (EPS) was defined as epigastric pain and epigastric burning for more than 6 months with symptoms. Age, sex, smoking, alcohol consumption, previous upper gastrointestinal studies, and previous medication were also recorded. Subjects who consumed alcohol more than 4 days a week, regardless of the amount, were considered to have a drinking habit. Smoking was defined as smoking any number of cigarettes daily. As judged by the physician, blood tests and further examinations such as esophagogastroduodenoscopy (EGD) and abdominal ultrasonography (US) were performed. A total of 24 subjects who had significant EGD or US findings, such as peptic ulcer disease, malignancies, gall stone, or abnormal results in laboratory parameters including ALT or WBC, was excluded from this study. Finally, 53 subjects were diagnosed as having FD, of which only 3 subjects also overlapped with IBS according to the ROME III criteria. As controls, people visiting the Healthcare Center of Social Insurance Shiga Hospital for an annual health check-up were asked to participate in the study. About 80% of those who underwent an annual health check-up from December 2007 to April 2008 agreed to participate in the study. Of the 1000 subjects who completed the same questionnaire, 646 subjects who did not have any symptoms of dyspepsia were included in this study. This study was approved by the ethics committees of both the Hyogo College of Medicine and the Social Insurance Shiga Hospital, and written informed consent was obtained from all participants.

Genotyping

DNA was isolated from whole blood from 699 participants by the alkaline lysis method using the QIAamp DNA Blood Maxi Kit (Qiagen Inc., Valencia, CA). The polymorphisms in the 5-HTTLPR were identified by polymerase chain reaction (PCR)-based fragment length polymorphisms. Polymorphisms were confirmed by direct sequencing. Oligonucleotide primers flanking the 5-HTTLPR long polymorphic region corresponding to the nucleotide positions 1651 to 1670 (sense 5' GCCGCTCTGAATGCCAGCAC 3') and 2242 to 2265 (antisense 5' GGAGGAACTGACC-CCTGAAAACTG 3') were used to generate 528- and/or 572-base-pair PCR-amplified fragments. Both sequences were obtained from the GenBank/EBI Data Bank, accession number X76753. PCR amplification was performed in a final volume of 20 μl, consisting of 0.2 μg of genomic DNA, 400 μmol/L deoxyribonucleotides, and 0.2 μmol/L of each primer. Because of the high guanine and cytosine (GC) content in the amplified region of the SERT gene (SLC6A4), the PCR reactions were performed using the TaKaRa La Taq polymerase (0.8 U/reaction) with GC Buffer I (TaKaRa Biomedicals, Shiga, Japan). After denaturing all DNA samples at 94°C for 1 min, cycling conditions were set at 30 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 2 min, with a 10-min final cycle extension at 72°C. To determine the presence of length variations of the alleles, amplified products were electrophoresed on 2.0% agarose and visualized by ethidium bromide staining.

Statistical Analysis

The median and range in each group were calculated, and differences were compared using the nonparametric Mann-Whitney U-test. Differences between 5-HTTLPR genotypes and sex, smoking, or drinking were compared by Fisher's exact test. The distribution of alleles at each locus was assessed using the χ2 statistic of the Hardy-Weinberg equilibrium. 5-HTTLPR genotypes were compared between FD patients and controls, and the association between specific types of FD and 5-HTTLPR polymorphism was assessed. A logistic regression analysis was performed to test the influence of several factors in the association between the 5-HTTLPR polymorphism genotype distribution and FD. P < 0.05 was considered significant. The Bonferroni correction was applied for multiple testing of each genotype.

Power of the Study

In this study, the potential association of symptoms of dyspepsia with 5-HTTLPR genotypes was assessed. In the healthy Japanese population, approximately 30% are expected to have the SL/LL genotype. Assuming that approximately 5% of subjects have symptoms of dyspepsia, a 20% increase in the prevalence of a genotype would be of clinical relevance. Thus, setting α = 0.05 and β = 0.80, 977 asymptomatic controls and 52 subjects with FD would be sufficient to identify a clinically relevant difference. The actual number of enrolled subjects (53 FD cases and 646 controls) has a power of 80% to detect the assumed difference. For the subgroup analyses for EPS (39 cases), and PDS (42 cases), the power to identify the assumed difference is 67%, and 70%, respectively.

Results

Participant demographics and 5-HTTLPR genotype distribution are summarized in Table 1. The median age of the subjects with dyspepsia and the non-dyspeptic controls was 52 (range, 21-82) and 45 (range, 19-78) years (P = 0.002). No significant bias was found between the groups for sex, smoking habit, and drinking habit. The 5-HTTLPR genotype distribution in all subjects in this study was 478 SS (68.4%), 194 SL (27.8%), and 27 LL (3.9%); this distribution was compatible with the Hardy-Weinberg equilibrium (P = 0.195). The 5-HTTLPR genotype distribution was 448 SS (69.3%), 174 SL (26.9%), and 24 LL (3.7%) in subjects without dyspepsia (controls), and 30 SS (56.6%), 20 SL (37.7%), and 3 LL (5.7%) in subjects with FD; both distributions were also compatible with the Hardy-Weinberg equilibrium. The distribution of the SS/SL/LL genotypes in the healthy controls was similar to other reports for Japanese populations [35, 36]. The distribution of allele and genotype frequencies did not differ significantly between males and females.
Table 1

Participant demographics and genotype distributions

 

Controls (n = 646)

FD, total (n = 53)

P 2

EPS (n = 39)4

P 2

PDS (n = 42)4

P 2

Age (years)1

45 (19-78)

52 (21-82)

0.002

50 (21-82)

0.021

51 (21-82)

0.015

Sex (male%)

50.5

49.1

0.887

41.0

0.323

52.4

0.874

Smoking (%)

32.7

28.3

0.647

23.1

0.289

31.0

1.000

Drinking (%)

29.6

32.1

0.755

30.8

0.858

33.3

0.604

5-HTTLPR genotype (%)

       

   SS

69.3

56.6

 

61.5

 

50.0

 

   SL

26.9

37.7

 

30.8

 

42.9

 

   LL

3.7

5.7

0.117

7.7

0.257

7.1

0.019

   P for HWE3

0.173

0.889

 

0.405

 

0.746

 

1Data are shown as median (range).

2P vs. controls by Mann-Whitney U-test (for age) or Fisher's exact test (for other variables).

3P for deviation from Hardy-Weinberg equilibrium (HWE).

4Twenty eight subjects are simultaneously classified EPS and PDS phenotype.

FD, functional dyspepsia; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome

The association of genotypes with the overall FD phenotype compared with asymptomatic controls was not significant (P = 0.117). Thirty-nine subjects had EPS, whereas 42 had PDS; 28 subjects simultaneously had EPS and PDS (Table 1). When the subtypes of FD and the genotypes were exploratory evaluated, a significant association of genotype in PDS subjects compared to that in control was detected (P = 0.019). On the other hand, no association of genotype in subjects with the EPS phenotype compared to that in controls was detected. The odds ratios of the 5-HTTLPR SL and LL genotypes relative to the SS genotype for the phenotypes of FD, EPS, PDS are shown in Table 2. Significant associations were detected for the SL genotypes in the PDS subtype [odds ratio (OR) = 2.24, 95% confidence interval (CI); 1.16-4.32, P = 0.033 after Bonferroni correction] adjusted for sex and age (Table 2). Comparison of the SS genotype with the SL/LL genotype also showed a significant association of genotype (OR = 2.32, 95% CI; 1.23-4.37, P = 0.009) (Table 2). However, there was no significant association of genotype detected in the FD and EPS phenotypes.
Table 2

Risk of dyspepsia according to 5-HTTLPR genotypes

 

FD, total (n = 53)

 

EPS (n = 39)1

 

PDS (n = 42)1

 
 

OR

(95%CI)

P

uncorrected (corrected)

OR

(95%CI)

P

uncorrected (corrected)

OR

(95%CI)

P

uncorrected (corrected)

5-HTTLPR genotype

         

SS

1

reference

 

1

reference

 

1

reference

 

SL

1.75

(0.96-3.19)

0.672

(1.000)

1.33

(0.65-2.73)

0.443

(0.886)

*2.24

(1.16-4.32)

0.017

(0.033)

LL

2.12

(0.59-7.59)

0.250

(0.499)

2.50

(0.69-9.10)

0.164

(0.328)

3.02

(0.83-11.06)

0.094

(0.188)

Recessive model

         

SS vs. SL+LL

1.79

(1.01-3.18)

0.472

1.46

(0.75-2.87)

0.268

*2.32

(1.23-4.37)

0.009

1Twenty eight subjects are simultaneously classified EPS and PDS phenotype.

FD, functional dyspepsia; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome;

OR, sex- and age-adjusted odds ratio, vs. 646 controls, by a multiple logistic regression model; CI, confidence interval.

* Significant P < 0.05

Discussion

In the present study, the prevalence of the 5-HTTLPR polymorphism was examined in dyspeptic patients in a Japanese population. Although the power was not enough for the analysis and the data are preliminary, the 5-HTTLPR L allele may be associated with an increased risk of PDS. Camilleri et al. and van Lelyveld et al. reported that the 5-HTTLPR polymorphism was not associated with dyspepsia in a population in the US and the Netherlands [33, 34]. The SERT mRNA expression in the gastric specimens of pediatric age FD patients was not significantly different compared with healthy controls [37]. These contrasting observations may be explained by differences in the genotypic composition of populations in different countries with different racial groups. In fact, the frequency of the LL subtype is lower in the Japanese population than in Caucasian populations [35, 36]. In addition, the definition of FD or sample selection may also affect the outcome. Moreover, the effect of type II error cannot be excluded in relatively small sample sizes. Another limitation of this study was that the ages were different in the groups. However, age adjustment was performed in genotype analysis using logistic regression.

The SERT is the target of selective serotonin re-uptake inhibitors (SSRI), which are widely used as antidepressants. Although SSRIs have been reported to have a benefit in IBS [38], few trials have focused on FD treatment. Any evidence of effectiveness is weak to nonexistent. Wu et al. conducted an open clinical trial with 40 FD patients. They reported that fluoxetine improved symptom scores in depressive FD patients [39]. Van Kerkhoven et al. conducted a randomized controlled trial with venlafaxine in 160 FD patients and showed no significant difference compared with placebo [40].

The results of the present study suggest the hypothesis that the 5-HTTLPR L allele may be associated with PDS. Based on in vitro studies of 5-HTTLPR polymorphism function, excessive transcription of SERT in 5-HTTLPR L allele would be expected to lead to higher 5-HT reuptake activity and decreased levels of 5-HT in the synaptic cleft [20], which in turn might result in decreased gut motility and secretion, subsequently causing postprandial fullness and early satiety, which are PDS symptoms. Actually after excluding subjects with both EPS and PDS, the association of SL genotype for the development of PDS was stronger (data not shown). However, the power was too small to conclude this from the present study. Furthermore, multiple testing may also affect the results. Therefore, we cannot exclude the effect of type I error.

The secreted 5-HT affects at least 30 subtypes of 7 main subclasses of serotonergic receptors that cause various effects on the gut or brain. There are several reports about the association between specific serotonergic receptors and dyspepsia. We have reported that the 5HT1A agonist tandospirone improved abdominal symptom scores, including upper abdominal pain and discomfort [41]. On the other hand, Tack et al. reported that a 5HT1A agonist failed to improve symptoms, visceral hypersensitivity, or gastric accommodation compared with placebo [42]. Boeckxstaens et al. also reported that a 5HT1A agonist had no effect on gastric fundus distension-evoked dyspeptic symptoms in healthy volunteers [43]. Talley et al. reported that alosetron, a 5HT3 antagonist, had potential benefit in relieving functional dyspepsia symptoms compared to placebo [44]. Maxton et al. and Kuo et al. also reported the effectiveness of alosetron for FD symptoms [45, 46]. In addition, Vakil et al. reported in their meta-analysis that tegaserod, a 5HT4 agonist, showed significant benefit in dysmotility, as occurs in FD [47].

Some reports seem to support our hypothesis, but there are several conflicting results. Therefore, the role of SERT functional differences in the gut is still unclear. The physiological effects on gut function of 5-HTTLPR polymorphism have been investigated in a report concerning IBS. However, there are many conflicting results [48].

Some studies have reported a sex relation in 5-HTTLPR polymorphism. Yeo et al. reported a significant association between D-IBS and 5-HTTLPR SS genotype in females [26]. A similar result for anxiety traits was reported by Mizuno et al. Females with the L/S genotype showed higher anxiety scores than males [49]. However, the sample size of this study was too small to conclude that there was a sex difference.

Conclusion

We have exploratory shown that 5-HTTLPR L allele may influence the susceptibility to PDS in a Japanese population. This is the first report that shows the possibility of a significant association between PDS and 5-HTTLPR polymorphism. FD is a complex and heterogeneous disorder, and it is known that FD is not caused by a single gene. Additional studies with a further larger sample and different polymorphisms are mandatory to identify the genetic background that influences susceptibility to FD.

List of abbreviations

FD: 

functional dyspepsia

5-HT: 

5-hydroxytryptamin (serotonin)

SERT: 

serotonin transporter

5-HTTLPR

5-HT transporter gene linked polymorphic region

GERD: 

gastroesophageal reflux disease

IBS: 

irritable bowel syndrome

PDS: 

postprandial distress syndrome

EPS: 

epigastric pain syndrome

EGD: 

esophagogastroduodenoscopy

US: 

ultrasonography

OR: 

odds ratio

CI: 

confidence interval.

Declarations

Acknowledgements

The authors would like to thank Ms. Noriko Kamiya and Ms. Masayo Togawa for their excellent technical assistance.

Authors’ Affiliations

(1)
Divisions of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine
(2)
Departments of Medicine, Gastroenterology and Health Care, Social Insurance Shiga Hospital
(3)
Divisions of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine

References

  1. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology. 2006, 130 (5): 1466-1479. 10.1053/j.gastro.2005.11.059.View ArticlePubMed
  2. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995, 40 (8): 1607-1613. 10.1007/BF02212678.View ArticlePubMed
  3. Salet GA, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ, Akkermans LM: Responses to gastric distension in functional dyspepsia. Gut. 1998, 42 (6): 823-829. 10.1136/gut.42.6.823.PubMed CentralView ArticlePubMed
  4. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998, 115 (6): 1346-1352. 10.1016/S0016-5085(98)70012-5.View ArticlePubMed
  5. Stanghellini V, Tosetti C, Paternico A, Barbara G, Morselli-Labate AM, Monetti N, Marengo M, Corinaldesi R: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 1996, 110 (4): 1036-1042. 10.1053/gast.1996.v110.pm8612991.View ArticlePubMed
  6. Greydanus MP, Vassallo M, Camilleri M, Nelson DK, Hanson RB, Thomforde GM: Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms. Gastroenterology. 1991, 100 (5 Pt 1): 1311-1318.PubMed
  7. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, Burger AL: Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988, 95 (3): 701-708.PubMed
  8. Locke GR, Weaver AL, Melton LJ, Talley NJ: Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol. 2004, 99 (2): 350-357. 10.1111/j.1572-0241.2004.04043.x.View ArticlePubMed
  9. Mahadeva S, Goh KL: Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006, 12 (17): 2661-2666.PubMed CentralPubMed
  10. Oshima T, Nakajima S, Yokoyama T, Toyoshima F, Sakurai J, Tanaka J, Tomita T, Kim Y, Hori K, Matsumoto T, Miwa H: The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet. 2010, 11: 13-PubMed CentralView ArticlePubMed
  11. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H: Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. Int J Mol Med. 2007, 20 (5): 717-723.PubMed
  12. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Hirata I: COMT gene val158met polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology. 2008, 55 (84): 979-982.PubMed
  13. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Yoshioka D, Okubo M, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nagasaka M, Iwata M, Takahama K, Watanabe M, Yamashita H, Nakano H, Hirata I: 779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. Hepatogastroenterology. 2009, 56 (93): 1245-1248.PubMed
  14. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H: Genetic polymorphisms of cyclooxygenase-1 (COX-1) are associated with functional dyspepsia in Japanese women. J Womens Health (Larchmt). 2008, 17 (6): 1039-1043. 10.1089/jwh.2007.0720.View Article
  15. Tahara T, Shibata T, Wang F, Nakamura M, Sakata M, Nakano H, Hirata I, Arisawa T: A genetic variant of the p22PHOX component of NADPH oxidase C242T is associated with reduced risk of functional dyspepsia in Helicobacter pylori-infected Japanese individuals. Eur J Gastroenterol Hepatol. 2009, 21 (12): 1363-1368. 10.1097/MEG.0b013e32830e2871.View ArticlePubMed
  16. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Hirata I, Arisawa T: Homozygous TRPV1 315C influences the susceptibility to functional dyspepsia. J Clin Gastroenterol. 2010, 44 (1): e1-7. 10.1097/MCG.0b013e3181b5745e.View ArticlePubMed
  17. Tahara T, Shibata T, Yamashita H, Hirata I, Arisawa T: The Role of RANTES Promoter Polymorphism in Functional Dyspepsia. J Clin Biochem Nutr. 2009, 45 (2): 235-240. 10.3164/jcbn.09-31.PubMed CentralView ArticlePubMed
  18. Kim D, Camilleri M: Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 2000, 95 (10): 2698-2709.PubMed
  19. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch K: Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996, 66 (6): 2621-2624.View ArticlePubMed
  20. Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S, Benjamin J, Müller C, Hamer D, Murphy D: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996, 274 (5292): 1527-1531. 10.1126/science.274.5292.1527.View ArticlePubMed
  21. Ogilvie A, Battersby S, Bubb V, Fink G, Harmar A, Goodwim G, Smith C: Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet. 1996, 347 (9003): 731-733. 10.1016/S0140-6736(96)90079-3.View ArticlePubMed
  22. Lin P, Tsai G: Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis. Biol Psychiatry. 2004, 55 (10): 1023-1030. 10.1016/j.biopsych.2004.02.006.View ArticlePubMed
  23. Kremer I, Bachner-Melman R, Reshef A, Broude L, Nemanov L, Gritsenko I, Heresco-Levy U, Elizur Y, Ebstein R: Association of the serotonin transporter gene with smoking behavior. Am J Psychiatry. 2005, 162 (5): 924-930. 10.1176/appi.ajp.162.5.924.View ArticlePubMed
  24. Ho P, Shih M, Ma K, Huang W, Ho K, Yen C, Lu R, Huang S: Availability of the serotonin transporter in patients with alcohol dependence. World J Biol Psychiatry. 2010
  25. Pata C, Erdal M, Derici E, Yazar A, Kanik A, Ulu O: Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol. 2002, 97 (7): 1780-1784. 10.1111/j.1572-0241.2002.05841.x.View ArticlePubMed
  26. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, Knaggs A, Asquith S, Taylor I, Bahari B, Rallan R, Varsani S, Montgomery D, Alpers DH, Dukes GE, Purvis I, Hicks GA: Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 2004, 53 (10): 1452-1458. 10.1136/gut.2003.035451.PubMed CentralView ArticlePubMed
  27. Park J, Choi M, Park J, Oh J, Cho Y, Lee I, Kim S, Choi K, Chung I: Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 2006, 18 (11): 995-1000. 10.1111/j.1365-2982.2006.00829.x.View ArticlePubMed
  28. Li Y, Nie Y, Xie J, Tang W, Liang P, Sha W, Yang H, Zhou Y: The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci. 2007, 52 (11): 2942-2949. 10.1007/s10620-006-9679-y.View ArticlePubMed
  29. Saito Y, Locke G, Zimmerman J, Holtmann G, Slusser J, De Andrade M, Petersen G, Talley N: A genetic association study of 5-HTT LPR and GN beta 3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterology and Motility. 2007, 465-470.
  30. Sikander A, Rana S, Sinha S, Prasad K, Arora S, Sharma S, Singh K: Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population. J Clin Gastroenterol. 2009, 43 (10): 957-961. 10.1097/MCG.0b013e3181b37e8c.View ArticlePubMed
  31. Niesler B, Kapeller J, Fell C, Atkinson W, Möller D, Fischer C, Whorwell P, Houghton LA: 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. Eur J Gastroenterol Hepatol. 2010, 22 (7): 856-861. 10.1097/MEG.0b013e32832e9d6b.View ArticlePubMed
  32. Markoutsaki T, Karantanos T, Gazouli M, Anagnou NP, Ladas SD, Karamanolis DG: Serotonin Transporter and G Protein Beta 3 Subunit Gene Polymorphisms in Greeks with Irritable Bowel Syndrome. Dig Dis Sci. 2011
  33. Camilleri C, Carlson P, Camilleri M, Castillo E, Locke Gr, Geno D, Stephens D, Zinsmeister A, Urrutia R: A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol. 2006, 101 (3): 581-592. 10.1111/j.1572-0241.2006.00481.x.View ArticlePubMed
  34. van Lelyveld N, Linde J, Schipper M, Samsom M: Candidate genotypes associated with functional dyspepsia. Neurogastroenterol Motil. 2008, 20 (7): 767-773. 10.1111/j.1365-2982.2008.01102.x.View ArticlePubMed
  35. Katsuragi S, Kunugi H, Sano A, Tsutsumi T, Isogawa K, Nanko S, Akiyoshi J: Association between serotonin transporter gene polymorphism and anxiety-related traits. Biol Psychiatry. 1999, 45 (3): 368-370. 10.1016/S0006-3223(98)00090-0.View ArticlePubMed
  36. Kumakiri C, Kodama K, Shimizu E, Yamanouchi N, Okada S, Noda S, Okamoto H, Sato T, Shirasawa H: Study of the association between the serotonin transporter gene regulatory region polymorphism and personality traits in a Japanese population. Neurosci Lett. 1999, 263 (2-3): 205-207. 10.1016/S0304-3940(99)00098-1.View ArticlePubMed
  37. Faure C, Patey N, Gauthier C, Brooks E, Mawe G: Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010, 139 (1): 249-258. 10.1053/j.gastro.2010.03.032.PubMed CentralView ArticlePubMed
  38. Ford A, Talley N, Schoenfeld P, Quigley E, Moayyedi P: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009, 58 (3): 367-378. 10.1136/gut.2008.163162.View ArticlePubMed
  39. Wu C, Chou L, Chen H, Chang C, Wong P, Chen G: Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology. 2003, 50 (49): 278-283.PubMed
  40. van Kerkhoven L, Laheij R, Aparicio N, De Boer W, Van den Hazel S, Tan A, Witteman B, Jansen J: Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008, 6 (7): 746-752. 10.1016/j.cgh.2008.02.051. quiz 718View ArticlePubMed
  41. Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T: Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009, 104 (11): 2779-2787. 10.1038/ajg.2009.427.View ArticlePubMed
  42. Tack J, Van Den Elzen B, Tytgat G, Wajs E, Van Nueten L, De Ridder F, Boeckxstaens G: A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil. 2009, 21 (6): 619-626. 10.1111/j.1365-2982.2008.01260.x. e623-614View ArticlePubMed
  43. Boeckxstaens G, Tytgat G, Wajs E, van Nueten L, de Ridder F, Meulemans A, Tack J: The influence of the novel 5-HT1A agonist R137696 on the proximal stomach function in healthy volunteers. Neurogastroenterol Motil. 2006, 18 (10): 919-926. 10.1111/j.1365-2982.2006.00812.x.View ArticlePubMed
  44. Talley N, Van Zanten S, Saez L, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel A: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001, 15 (4): 525-537. 10.1046/j.1365-2036.2001.00941.x.View ArticlePubMed
  45. Maxton D, Morris J, Whorwell P: Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?. Aliment Pharmacol Ther. 1996, 10 (4): 595-599. 10.1046/j.1365-2036.1996.30172000.x.View ArticlePubMed
  46. Kuo B, Camilleri M, Burton D, Viramontes B, McKinzie S, Thomforde G, O'Connor M, Brinkmann B: Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther. 2002, 16 (2): 225-233. 10.1046/j.1365-2036.2002.01144.x.View ArticlePubMed
  47. Vakil N, Laine L, Talley N, Zakko S, Tack J, Chey W, Kralstein J, Earnest D, Ligozio G, Cohard-Radice M: Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008, 103 (8): 1906-1919.PubMed
  48. Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del Tacca M: The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med. 2008, 14 (7): 295-304. 10.1016/j.molmed.2008.05.001.View ArticlePubMed
  49. Mizuno T, Aoki M, Shimada Y, Inoue M, Nakaya K, Takahashi T, Itoyama Y, Kanazawa M, Utsumi A, Endo Y, Nomura T, Hiratsuka M, Mizugaki M, Goto J, Hongo M, Fukudo S: Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. J Psychosom Res. 2006, 60 (1): 91-97. 10.1016/j.jpsychores.2005.06.068.View ArticlePubMed
  50. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2350/​12/​88/​prepub

Copyright

© Toyoshima et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.